Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
CHRNA3 1136 VARENICLINE CHEMBL1396 partial agonist TdgClinicalTrial, DrugBank 16766716
CHRNA3 1136 PENTOLINIUM TARTRATE CHEMBL1318287 antagonist ChemblInteractions
CHRNA3 1136 PENTOLINIUM CHEMBL1271 antagonist DrugBank 7761270
CHRNA3 1136 TC-6499 CHEMBL3545353 agonist ChemblInteractions
CHRNA3 1136 TRIMETHAPHAN CAMSYLATE CHEMBL1245 antagonist ChemblInteractions
CHRNA3 1136 CYTISINE CHEMBL497939 agonist DrugBank 11553677, 25517706
CHRNA3 1136 LARAZOTIDE ACETATE CHEMBL2103815 partial agonist ChemblInteractions
CHRNA3 1136 LEVAMISOLE CHEMBL1454 agonist DrugBank 17139284, 17016423, 17629760, 15280391, 17314321, 19668355, 10592235
CHRNA3 1136 MECAMYLAMINE HYDROCHLORIDE CHEMBL1237082 ChemblInteractions
CHRNA3 1136 ASM-024 CHEMBL3707249 antagonist ChemblInteractions
CHRNA3 1136 LEVOMETHADYL ACETATE CHEMBL1514 antagonist DrugBank 11561100

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
CHRNA3 rs578776 A nicotine metabolism/PK no The A allele of s578776 was significantly associated with 8% lower cotinine levels, but the association was no longer significant after adjusting for rs16969968 (the per allele effect size was -8.2 ng/mL, CI = -20.24–3.93 and P = 0.19 vs. -18.9 ng/mL without adjustment P = 0.002 ). Allele A is not associated with dose of nicotine in people with Tobacco Use Disorder as compared to allele G. 26010901 1444930293
CHRNA3 rs1051730 A nicotine metabolism/PK yes Serum Cotinine levels were measured to test for association between nicotine intake and this SNP. AA>AG>GG for serum cotinine levels in daily smokers. Authors noted that the variance was very high (R-squared = 4.3%). Effect size of this SNP was 0.30 . Cigarettes per day was also associated but not significantly so after correction for multiple testing. Allele A is associated with increased dose of nicotine as compared to allele G. 19628476 981750833
CHRNA3 rs578776 GG nicotine efficacy no Response here refers to smoking cessation outcomes at 7 days and nicotine refers to nicotine patches. Smoking cessation outcomes at 6 months and 12 months were also not significantly associated with genotype. Genotype GG is not associated with response to nicotine or varenicline in people with Tobacco Use Disorder as compared to genotypes AA + AG. 26010901 1444930252
CHRNA3 rs660652 A nicotine other no No significant association between this allele and status as a smoker or non-smoker. Allele A is not associated with exposure to nicotine in men as compared to allele G. 29666375 1450930612
CHRNA3 rs2869546 C nicotine other no No significant association between this allele and status as a smoker or non-smoker. Allele C is not associated with exposure to nicotine in men as compared to allele T. 29666375 1450930617
CHRNA3 rs1051730 A nicotine dosage yes Each copy of the minor A allele was associated with a 2.9% decrease in nicotine replacement therapy (NRT) adherence and a 1mg decrease in NRT consumption at 7 days after quit attempt. The association between the A allele and decreased NRT adherence lost significance following adjustment for number of cigarettes smoked. No association between this allele and NRT adherence or consumption was seen at 28 days post quit attempt. Allele A is associated with decreased dose of nicotine in people with Tobacco Use Disorder as compared to allele G. 25891233 1450821968
CHRNA3 rs3743075 T nicotine other no No significant association between this allele and status as a smoker or non-smoker. Allele T is not associated with exposure to nicotine in men as compared to allele C. 29666375 1450930590
CHRNA3 rs3743077 T nicotine other no No significant association between this allele and status as a smoker or non-smoker. Allele T is not associated with exposure to nicotine in men as compared to allele C. 29666375 1450930607
CHRNA3 rs1051730 A bupropion efficacy no No significant effect of genotype on likelihood of being abstinent from smoking at 6 months after starting pharmacotherapy for smoking cessation. Please note that alleles have been complemented to the positive strand. Allele A is not associated with response to bupropion, nicotine or varenicline in people with Tobacco Use Disorder as compared to allele G. 29621993 1450928798
CHRNA3 rs3743074 G nicotine other no No significant association between this allele and status as a smoker or non-smoker. Allele G is not associated with exposure to nicotine in men as compared to allele A. 29666375 1450930597
CHRNA3 rs7170068 A cotinine metabolism/PK yes The authors conducted a GWAS meta-analysis to identify genetic variants associated with cotinine in current daily smokers (Caucasian). The following study cohorts were analyzed: ALSPAC, CARDIA, FinnTwin, Framingham, GenMets, MESA, NESDA, NTR, TwinsUK, YFS. This SNP was detected as a residual association after accounting for rs16969968. Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele G. 26833182 1447814229
CHRNA3 rs6495307 T nicotine other no No significant association between this allele and status as a smoker or non-smoker. Allele T is not associated with exposure to nicotine in men as compared to allele C. 29666375 1450930602